Work

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma

Year: 2017

Type: article

Abstract: Elotuzumab is one of the first monoclonal antibodies to be approved for the treatment of multiple myeloma. It is a humanized immunoglobulin G kappa (IgGκ) antibody that targets signaling lymphocytic activation molecule family member 7 (SLAMF7), a surface marker that is highly expressed on normal and malignant plasma cells. This review summarizes the preclinical and clinical data that led to the approval of elotuzumab, along with a discussion on the ongoing and future clinical investigations.

Source: Drug Design Development and Therapy

DOI: 10.2147/dddt.s98053

Authors: Reed Friend, Manisha Bhutani, Peter Voorhees, Saad Usmani

Institutions: Carolinas Healthcare System, Levine Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,836